Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

NCT05851105 is registered in ClinicalTrials.gov with Shenzhen Hemogen as lead sponsor.

NCT NCT05851105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05851105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
Lead sponsor
Shenzhen Hemogen
Phase
Phase 1
Overall status
Recruiting
Start date
October 8, 2022
Completion date
December 30, 2026
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

α-thalassemia